- Altos Labs – a $3 billion biotech startup backed by Jeff Bezos – is on a mission to restore cell health and reverse diseases by rejuvenating cells labiotech.eu. It launched in 2022 with a dream of extending healthy human lifespan.
- Not about “cheating death”: Altos’s president Hans Bishop insists the focus is on extending “healthspan” (years of healthy life), with any longevity gains merely an “accidental consequence” fightaging.org. The company emphasizes improving life quality over pursuing immortality.
- Unprecedented talent & funding: Altos assembled a “dream team” of scientists – including Nobel laureate Shinya Yamanaka – by offering academic freedom and industry-level resources. Led by former GSK executive Hal Barron as CEO, and co-founded by biotech veterans Richard Klausner and Hans Bishop, Altos attracted $3 billion from prominent investors (Bezos, Yuri Milner, Arch Ventures) labiotech.eu en.wikipedia.org, making it one of the best-funded startups in biotech history.
- Racing a booming longevity industry: Altos Labs is part of a broader anti-aging biotech boom. Alphabet’s Calico Labs (launched 2013) was a pioneer, and newer startups like Retro Biosciences and Loyal have joined the fray – all aiming to extend healthy lifespan via cutting-edge science and drawing investments from Silicon Valley billionaires businessinsider.com 1 .
- Innovations in “rejuvenation” science: Altos and its peers are leveraging breakthroughs like partial cellular reprogramming – using Yamanaka factors to reset adult cells to a youthful state – which has shown promise in animals labiotech.eu labiotech.eu. Other approaches include senolytic drugs to clear aged “zombie” cells and gene therapies, all targeting aging at its biological roots.
- Early results signal hope: In 2024, Altos scientists published a landmark study demonstrating that partial reprogramming extended the lifespan of mice and improved health markers labiotech.eu. This evidence that aging may be reversible has been hailed as a major step toward translating rejuvenation technologies to humans.
- Competition and collaboration: Companies like Retro Biosciences (funded by OpenAI’s Sam Altman) aim to add 10+ years to human life through cell reprogramming and autophagy, planning their first clinical trials and reportedly seeking $1 billion for next steps labiotech.eu labiotech.eu. Loyal, which has raised over $125 million, is developing drugs to extend dogs’ lifespans as a springboard to human applications – and expects to launch the first FDA-approved longevity drug for pets by 2025 2 3
Inside Altos Labs: Jeff Bezos’s $3 Billion Bet to Reverse Aging
Stock Market Today
Snap stock price bounces to $5.22 after upgrades — what traders watch next week
Snap Inc. shares closed up 2% at $5.22 Friday after a volatile week, with 94 million shares traded. The company forecast Q1 revenue below analyst expectations, despite a fourth-quarter beat and a 28% rise in active advertisers. Daily active users fell by 3 million to 474 million. Analysts remain divided, with some upgrading and others trimming price targets.
Bradesco stock drops on 2026 guidance — what BBDC4 investors watch next week
Bradesco’s preferred shares fell 2.55% to 20.61 reais Friday after the bank issued 2026 guidance pointing to slower growth in some areas. Fourth-quarter recurring net income rose 20.6% to 6.5 billion reais, with 2025 ROAE at 15.2%. The Ibovespa closed up 0.45%. Bradesco ADRs ended down 0.5% at $3.98 in New York.
Stellantis stock slides 24% after €22 billion EV reset kills 2026 dividend — what to watch next
Stellantis shares plunged 23.7% to $7.28 Friday after the company disclosed about €22.2 billion in charges tied to a reset of its electric-vehicle strategy and said it will skip its 2026 dividend. The automaker flagged a preliminary net loss of €19–21 billion for the second half of 2025. Shares rose 1.6% in late after-hours trading. Investors await Feb. 26 results and a May 21 Investor Day.
Intel stock jumps on China server CPU delays as traders map the week ahead
Intel shares rose 4.87% to $50.59 Friday, trailing gains by Nvidia and Broadcom as chip stocks rallied. Sources said Intel and AMD warned Chinese customers of longer waits and higher prices for some server CPUs, with Intel lead times reaching six months. Intel said China accounts for over 20% of its revenue. Investors await key U.S. jobs and inflation data next week.
